Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 2.91%5.83B | 1.49%3.62B | --1.59B | -12.10%7.67B | --5.66B | -6.44%3.57B | -37.96%8.73B | -36.54%3.81B | 247.15%14.07B | --6.01B |
| Operating income | 2.91%5.83B | 1.49%3.62B | 1.59B | -12.10%7.67B | 5.66B | -6.44%3.57B | -37.96%8.73B | -36.54%3.81B | 247.15%14.07B | 6.01B |
| Cost of sales | ---- | 3.22%-3.12B | ---- | 20.31%-7B | ---- | 20.49%-3.22B | 24.50%-8.79B | 15.79%-4.06B | -291.37%-11.64B | ---4.82B |
| Operating expenses | -0.64%-5.03B | 3.22%-3.12B | -1.33B | 20.31%-7B | -5B | 20.49%-3.22B | 24.50%-8.79B | 15.79%-4.06B | -291.37%-11.64B | -4.82B |
| Gross profit | 19.91%798.09M | 45.71%501.19M | 266.28M | 1,266.80%670.69M | 665.56M | 242.47%343.97M | -102.36%-57.48M | -120.22%-241.43M | 125.36%2.43B | 1.19B |
| Selling expenses | -4.52%-120.87M | 13.71%-69.61M | ---34.94M | 16.68%-163.76M | ---115.65M | 23.67%-80.67M | -11.13%-196.54M | -35.60%-105.68M | -2.37%-176.86M | ---77.94M |
| Administrative expenses | -4.40%-291.33M | 0.32%-274.7M | ---88.11M | 28.37%-622.43M | ---279.06M | 21.41%-275.6M | -171.73%-868.97M | -250.57%-350.7M | -104.38%-319.8M | ---100.04M |
| Research and development expenses | 16.12%-310.76M | 7.25%-190.09M | ---104.93M | 0.37%-483.92M | ---370.48M | 22.84%-204.95M | 21.09%-485.72M | -31.05%-265.63M | -196.00%-615.55M | ---202.7M |
| Profit from asset sales | -199.72%-950.75K | ---- | ---7.11K | ---- | --953.41K | ---- | ---- | ---- | ---- | ---- |
| Revaluation surplus | -183.06%-25.45M | ---- | ---1.45M | ---- | ---8.99M | ---- | ---- | ---- | ---- | ---- |
| -Changes in the fair value of other assets | -183.06%-25.45M | ---- | ---1.45M | ---- | ---8.99M | ---- | ---- | ---- | ---- | ---- |
| Impairment and provision | 3.29%-108.95M | -136.38%-11.08M | ---31.36M | 256.22%29.63M | ---112.66M | -16.17%30.46M | 73.05%-18.97M | 175.04%36.33M | -204.15%-70.36M | ---48.42M |
| -Other impairment is provision | 3.29%-108.95M | -136.38%-11.08M | ---31.36M | 256.22%29.63M | ---112.66M | -16.17%30.46M | 73.05%-18.97M | 175.04%36.33M | -204.15%-70.36M | ---48.42M |
| Special items of operating profit | 17.16%153.62M | -27.74%96.92M | --43.79M | 66.59%136.72M | --131.12M | 104.20%134.12M | -13.91%82.07M | 88.79%65.68M | 155.48%95.34M | --34.79M |
| Operating profit | 147.22%56.15M | 199.92%52.63M | 36.72M | 71.98%-433.08M | -118.92M | 93.89%-52.67M | -214.82%-1.55B | -207.71%-861.42M | 141.77%1.35B | 799.77M |
| Financing cost | 3.80%-178.39M | -8.19%-141.08M | ---74.5M | 1.04%-258.66M | ---185.44M | -20.23%-130.4M | -29.30%-261.38M | -28.09%-108.46M | -306.26%-202.14M | ---84.67M |
| Share of profits of associates | ---- | 25.02%-8.91M | ---- | -21.90%-28.75M | ---- | -347.01%-11.88M | -239.08%-23.58M | -84.64%-2.66M | 6,177.42%16.96M | ---1.44M |
| Adjustment items of earning before tax | -23.69%7.45M | ---- | --2.84M | ---- | --9.77M | ---- | ---- | ---- | ---- | ---- |
| Earning before tax | 61.04%-114.79M | 50.06%-97.36M | -34.95M | 60.64%-720.49M | -294.59M | 79.96%-194.94M | -257.69%-1.83B | -236.27%-972.54M | 129.10%1.16B | 713.66M |
| Tax | 78.88%-16.49M | 82.38%-11.75M | ---6.41M | -123.98%-75.88M | ---78.09M | -141.41%-66.69M | 341.61%316.37M | 260.00%161.05M | -78.63%-130.94M | ---100.66M |
| After-tax profit from continuing operations | 64.78%-131.28M | 58.30%-109.11M | -41.36M | 47.41%-796.37M | -372.68M | 67.76%-261.63M | -247.02%-1.51B | -232.38%-811.49M | 137.63%1.03B | 613.01M |
| Earning after tax | 64.78%-131.28M | 58.30%-109.11M | -41.36M | 47.41%-796.37M | -372.68M | 67.76%-261.63M | -247.02%-1.51B | -232.38%-811.49M | 137.63%1.03B | 613.01M |
| Minority profit | 70.17%-20.8M | 41.24%-24.92M | ---15.41M | 41.86%-163.33M | ---69.75M | 73.08%-42.4M | -201.39%-280.91M | -187.65%-157.48M | 236.57%277.05M | --179.67M |
| Profit attributable to shareholders | 63.53%-110.47M | 61.60%-84.19M | -25.95M | 48.67%-633.04M | -302.93M | 66.48%-219.23M | -263.81%-1.23B | -250.92%-654.01M | 114.44%752.9M | 433.33M |
| Basic earnings per share | 70.37%-0.16 | 69.23%-0.12 | -0.04 | 50.23%-1.09 | -0.54 | 66.38%-0.39 | -253.15%-2.19 | -230.34%-1.16 | 95.89%1.43 | 0.89 |
| Diluted earnings per share | 70.37%-0.16 | 69.23%-0.12 | -0.04 | 50.23%-1.09 | -0.54 | 66.38%-0.39 | -254.23%-2.19 | -231.82%-1.16 | 94.52%1.42 | 0.88 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | -- | Unqualified Opinion | -- |
| Auditor | -- | -- | -- | Gongzheng Tianye Certified Public Accountants (Special General Partnership) | -- | -- | Dahua Ma Shiyun Certified Public Accountants Co., Ltd. | -- | Dahua Ma Shiyun Certified Public Accountants Co., Ltd. | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.